KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Research & Development (2016 - 2022)

TherapeuticsMD's Research & Development history spans 12 years, with the latest figure at $1.1 million for Q3 2022.

  • For Q3 2022, Research & Development fell 30.72% year-over-year to $1.1 million; the TTM value through Sep 2022 reached $5.5 million, down 31.61%, while the annual FY2021 figure was $7.1 million, 32.07% down from the prior year.
  • Research & Development reached $1.1 million in Q3 2022 per TXMD's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $7.0 million in Q1 2018 to a low of $1.1 million in Q3 2022.
  • Average Research & Development over 5 years is $3.6 million, with a median of $2.7 million recorded in 2020.
  • Peak YoY movement for Research & Development: rose 4.22% in 2018, then plummeted 50.29% in 2020.
  • A 5-year view of Research & Development shows it stood at $6.8 million in 2018, then tumbled by 34.37% to $4.4 million in 2019, then tumbled by 45.98% to $2.4 million in 2020, then tumbled by 40.69% to $1.4 million in 2021, then fell by 21.69% to $1.1 million in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Research & Development are $1.1 million (Q3 2022), $1.6 million (Q2 2022), and $1.4 million (Q1 2022).